These reminder cards, created in partnership with the Colorado Department of Public Health and Environment (CDPHE),Ā are a tool that can be used by healthcare professionals to help remind parents which vaccines their child needs, and remind adults which vaccines they need. The card can folded, taped, and mailed to patients, or hand-delivered at a wellness exam. The childhood card includes all recommended childhood and adolescent vaccines, and the adult card includes all recommended adult vaccines. The cards are both available in English and Spanish.
New cancer vaccine finds way to overcome tumor defenses
Developing cancer vaccines have been an essential partTrusted Source of cancer research for almost three decades.
Many formsTrusted Source of cancer vaccines are under research, including those that target proteins expressed across multiple cancer types, and those that are personalizedTrusted Source according to individual tumor mutations.
While existing vaccines can induce an immune response in blood, tumors often dodge this response via an immune escape mechanism.
Targeting this mechanism may help researchers improve cancer vaccine efficacy.
In a recent study, researchers developed a new cancer vaccine that targets this immune escape mechanism and increases immune antibody levels.
FDA Panel Recommends Moderna and Pfizer COVID-19 Vaccines for Children 6 Months and Older
Many parents in the U.S. have been waiting to hear that the nationās youngest childrenāthose under 5 years oldācan be vaccinated against COVID-19. Finally, on June 15, an expert panel convened by the U.S. Food and Drug Administration (FDA) said that two vaccines, made by Pfizer-BioNTech and Moderna, are safe and effective for children ages 6 months and older.
The FDAās panel voted unanimouslyā21-0āthat the benefits of Modernaās vaccine outweigh its risks for kids ages 6 months through 5 years of age. They also voted unanimously that the benefits of Pfizer-BioNTechās vaccine outweigh risks for kids ages 6 months through 4 years.
FDA advisers back Moderna’s COVID-19 vaccine for older kids
NEW YORK — A government advisory panel Tuesday endorsed a second brand of COVID-19 vaccine for school-age children and teens.
The Food and Drug Administration’s outside experts voted unanimously that Moderna’s vaccine is safe and effective enough to give kids ages 6 to 17. If the FDA agrees, it would become the second option for those children, joining Pfizer’s vaccine.
COVID-19 Continues to ‘Unravel’ Progress on Routine Vaccinations
New reports suggest that many people are not still caught up on routine vaccine schedules that were disrupted by missed appointments throughout the pandemic.1
The reports suggest stay-at-home orders, fear of COVID-19 exposure, and healthcare staffing shortages have likely contributed to the decrease in vaccinations forĀ measles, hepatitis A and B, meningitis, tetanus, and more. As pandemic restrictions ease up, immunization rates have yet to rebound enough to make up for the decline.
Op-Ed:Ā Vaccine disruptions and mistrust are ramping up measles risk
Pandemics have consequences beyond the death and disease directly caused by the novel pathogen. In the 1918 influenza pandemic, more deaths were caused by the pneumococcal bacterium among those made susceptible to bacterial infection by influenza than by the flu itself.
One potential byproduct of the devastating COVID-19 pandemic is the threat of an old scourge: measles. In the United States,Ā two doses of measles vaccinesĀ are recommended for all children. These doses are usually administered as the measles, mumps and rubella combined vaccine. The first dose is given at 12 to 15 months of age, and the second dose at 4 to 6 years of age.Ā Schools in all statesĀ require measles vaccination for entry, though they allow various medical or nonmedical exemptions.
U.S. orders 500,000 monkeypox vaccines to be delivered this year
The United States has ordered 500,000 more monkeypox vaccine doses for delivery this year, the manufacturer said Friday.
The order islarger than earlier onesto the U.S. ā including 36,000 doses to be delivered this week ā and represents a significant escalation in the fight against a growing monkeypox outbreak.
Marathon US hearings to decide fate of COVID shots for tots
Parents anxious to finally vaccinate their youngest children against COVID-19, strap in: A lot is set to happen over the next week.
On Wednesday, both Moderna and Pfizer will have to convince whatās essentially a science court — advisers to the Food and Drug Administration — that their shots work well in babies, toddlers and preschoolers.
FDA Approves Priorix Vaccine for Measles, Mumps, and Rubella
The FDA has approved Priorix (measles, mumps and rubella [MMR] vaccine, live; GSK) active immunization for the prevention of measles, mumps, and rubella (MMR) in individuals 12 months of age and older. Priorix can be administered as a first dose, followed by a second dose of the vaccine, or as a second dose to those previously administered the first dose of another MMR-containing vaccine.
The efficacy ofĀ Priorix was demonstrated based on immunogenicity data versus the comparator vaccine, according to GSK. The vaccineĀ is set to be on the agenda this month for review by the CDC Advisory Committee on Immunization Practices for consideration of formal inclusion into the vaccine schedule and recommendations.
Why boosted Americans seem to be getting more COVID-19 infections
As COVID-19 cases began to accelerate again this spring, federal data suggests the rate of breakthrough COVID infections in April was worse in boosted Americans compared to unboosted Americans ā though rates of deaths and hospitalizations remained the lowest among the boosted.
The new data do not meanĀ booster shotsĀ are somehow increasing the risk.Ā Ongoing studiesĀ continue to provide strong evidence of additional protection offered by booster shots against infection, severe disease, and death.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 36
- Next Page »